|
The acceleration of biomedical research and clinical trials in response to the COVID-19 pandemic is providing hope and revealing new opportunities for partnership between private industry and academic research labs. Dale Chappell, MD, MBA, MED’99 will discuss how his company, Humanigen, received FDA approval to test their lead cancer immunotherapy as a potential treatment for COVID-19. The drug is now in Phase III clinical trials at Dartmouth-Hitchcock Medical Center and other academic hospitals across the U.S. Dartmouth virologist David Leib, PhD, will share how his lab collaborated with Atila Biosystems to validate a rapid, low-cost COVID-19 diagnostic test—which recenty received FDA emergency authorization and is being adopted by multiple countries. This discussion will be led by Barry Schweitzer, PhD, D’82, who oversees biomedical academic-industry partnerships for the Technology Transfer Office at Dartmouth College. Attendees are invited to submit questions during the webinar.
|
Register Now
May 22, 2020
12:00 – 1:30 pm (ET)
|